Literature DB >> 29566126

Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy.

Ibrahim El-Battrawy1,2, Zhihan Zhao1,2, Huan Lan1,2,3, Lukas Cyganek2,4, Christoph Tombers1, Xin Li1, Fanis Buljubasic1,2, Siegfried Lang1,2, Malte Tiburcy2,5, Wolfram-Hubertus Zimmermann2,5, Jochen Utikal2,6,7, Thomas Wieland2,8, Martin Borggrefe1,2, Xiao-Bo Zhou1,2,3, Ibrahim Akin1,2.   

Abstract

Aims: Our aim is to investigate the arrhythmogenic mechanism in arrhythmogenic right ventricular cardiomyopathy (ARVC)-patients by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Methods and results: Human-induced pluripotent stem cell-derived cardiomyocytes were generated from human skin fibroblasts of two healthy donors and an ARVC-patient with a desmoglein-2 (DSG2) mutation. Patch clamp, quantitative polymerase chain reaction, and calcium imaging techniques were employed for the study. The amplitude and maximal upstroke velocity (Vmax) of action potential (AP) in ARVC-cells were smaller than that in healthy donor cells, whereas the resting potential and AP duration (APD) was not changed. The reduced Vmax resulted from decreased peak sodium current. The reason for undetected changes in APD may be the counter-action of reduced transient outward, small conductance Ca2+-activated, adenosine triphosphate-sensitive, Na/Ca exchanger (INCX) currents, and enhanced rapidly delayed rectifier currents. Isoprenaline (Iso) reduced INCX and shortened APD in both donor and ARVC-hiPSC-CMs. However, the effects of Iso in ARVC-cells are significantly larger than that in donor cells. In addition, ARVC-hiPSC-CMs showed more frequently than donor cells arrhythmogenic events induced by adrenergic stimulation.
Conclusion: Cardiomyocytes derived from the ARVC patient with a DSG2 mutation displayed multiple ion channel dysfunctions and abnormal cellular electrophysiology as well as enhanced sensitivity to adrenergic stimulation. These may underlie the arrhythmogenesis in ARVC patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29566126     DOI: 10.1093/europace/euy042

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  21 in total

1.  Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Fanis Buljubasic; Ibrahim El-Battrawy; Huan Lan; Santosh K Lomada; Anupriya Chatterjee; Zhihan Zhao; Xin Li; Rujia Zhong; Qiang Xu; Mengying Huang; Zhenxing Liao; Siegfried Lang; Lukas Cyganek; Xiaobo Zhou; Thomas Wieland; Martin Borggrefe; Ibrahim Akin
Journal:  J Clin Med       Date:  2020-02-10       Impact factor: 4.241

Review 2.  Molecular mechanisms of arrhythmogenic cardiomyopathy.

Authors:  Karyn M Austin; Michael A Trembley; Stephanie F Chandler; Stephen P Sanders; Jeffrey E Saffitz; Dominic J Abrams; William T Pu
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

Review 3.  Calcium as a Key Player in Arrhythmogenic Cardiomyopathy: Adhesion Disorder or Intracellular Alteration?

Authors:  Francesco Moccia; Francesco Lodola; Ilaria Stadiotti; Chiara Assunta Pilato; Milena Bellin; Stefano Carugo; Giulio Pompilio; Elena Sommariva; Angela Serena Maione
Journal:  Int J Mol Sci       Date:  2019-08-16       Impact factor: 5.923

Review 4.  Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies.

Authors:  Andreas Brodehl; Hans Ebbinghaus; Marcus-André Deutsch; Jan Gummert; Anna Gärtner; Sandra Ratnavadivel; Hendrik Milting
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

5.  Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Ibrahim El-Battrawy; Jonas Müller; Zhihan Zhao; Lukas Cyganek; Rujia Zhong; Feng Zhang; Mandy Kleinsorge; Huan Lan; Xin Li; Qiang Xu; Mengying Huang; Zhenxing Liao; Alexander Moscu-Gregor; Sebastian Albers; Hendrik Dinkel; Siegfried Lang; Sebastian Diecke; Wolfram-Hubertus Zimmermann; Jochen Utikal; Thomas Wieland; Martin Borggrefe; Xiaobo Zhou; Ibrahim Akin
Journal:  Front Cell Dev Biol       Date:  2019-11-01

Review 6.  Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine.

Authors:  Ziwei Pan; Antje Ebert; Ping Liang
Journal:  Pflugers Arch       Date:  2020-11-18       Impact factor: 3.657

Review 7.  Uncovering Inherited Cardiomyopathy With Human Induced Pluripotent Stem Cells.

Authors:  Xue Jiang; Yihuan Chen; Xiaofeng Liu; Lingqun Ye; Miao Yu; Zhenya Shen; Wei Lei; Shijun Hu
Journal:  Front Cell Dev Biol       Date:  2021-05-17

Review 8.  Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research.

Authors:  Kalina Andrysiak; Jacek Stępniewski; Józef Dulak
Journal:  Pflugers Arch       Date:  2021-02-24       Impact factor: 3.657

9.  Enrichment differentiation of human induced pluripotent stem cells into sinoatrial node-like cells by combined modulation of BMP, FGF, and RA signaling pathways.

Authors:  Feng Liu; Yibing Fang; Xiaojie Hou; Ying Yan; Haiying Xiao; Dongchuan Zuo; Jing Wen; Linli Wang; Zhichao Zhou; Xitong Dang; Rui Zhou; Bin Liao
Journal:  Stem Cell Res Ther       Date:  2020-07-16       Impact factor: 6.832

Review 10.  Inherited cardiac diseases, pluripotent stem cells, and genome editing combined-the past, present, and future.

Authors:  Lettine van den Brink; Catarina Grandela; Christine L Mummery; Richard P Davis
Journal:  Stem Cells       Date:  2019-12-16       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.